Clinical Trial Update: A Study to Assess Efficacy, Safety and Tolerability of the Anti-IL-13 Monoclonal Antibody QAX576 in the Treatment of Perinanal Fistulas in Patients Suffering From Crohn's Disease [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the anti-IL-13 monoclonal antibody QAX576 for perianal fistulas in Crohn's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• QAX576

Snippet

Sponsor: Gerhard Rogler | Conditions: Crohn's Disease | Phase 2 | Status: COMPLETED